Search Results 1101-1110 of 19340 for hemoglobin

1. A Study to Evaluate Genetic Testing in Guiding Treatment for Patients with Brain Metastases - Mayo Clinic

   Hemoglobin ≥ g/dL. Patients may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator. Initial treatment ...

2. Muscle and Adipose Trafficking of Fatty Acids Under Hypoinsulinemic and Fed Conditions - Mayo Clinic

   Normal hemoglobin >11.0 g/dL for women and men will be acceptable. Women of child-bearing potential will complete a urine pregnancy test at each visit.

3. Ravulizumab in Immunoglobulin A Nephropathy (IgAN) - Mayo Clinic

   * Uncontrolled diabetes mellitus with glycosylated hemoglobin (HbA1c) \> 8.5%. * Clinically active Henoch-Schonlein purpura (IgA vasculitis) requiring ...

4. Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations - Mayo Clinic

   Hemoglobin ≥ 9.0 g/dL; Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN); Aspartate transaminase (AST); alanine aminotransferase (ALT) ...

5. Intracranial hematoma - Symptoms and causes - Mayo Clinic

   It's usually caused by a blood vessel that bursts in the brain. It also may be caused by a head injury due to a car accident or fall.

6. Phase I/II Trial to Investigate BI 836858 in Myelodysplastic Syndromes - Mayo Clinic

   Phase I/II: Patients must have received ≥ 2 units of RBCs for hemoglobin ≤ 9.0 g/dL within 8 weeks prior to start of treatment. Patient is non-responsive ...

7. Efficacy and Safety of Seralutinib in Adult Subjects With PAH - Mayo Clinic

   Estimated glomerular filtration rate (eGFR) \< 45 mL/min/1.73m\^2 Hemoglobin (Hgb) concentration \< 8.5 g/dL at Screening. 19. Evidence of active or latent ...

8. A Study to Evaluate Mutanome-directed Immunotherapy in Patients with Squamous Cell Carcinoma of the Head and Neck - Mayo Clinic

   Participation eligibility · Hemoglobin ≥ 9.0 g/dL; · Neutrophils count ≥ 1.5 x10^9 /L; · Total lymphocytes count ≥ 0.5 x10^9 /L; · Platelets count ≥ 100 x10^9 / ...

9. A Study to Evaluate the Safety and Effectiveness of MOR202 in Anti-PLA2R Antibody-positive Membranous Nephropathy - Mayo Clinic

   Participation eligibility · Hemoglobin* < 90 g/L; · Thrombocytopenia**:. Platelets < 100.0 x 10^9 /L; · Neutropenia***: Neutrophils < 1.5 x 10^9 /L; · Leukopenia*** ...

10. Testing the Addition of Ixazomib to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial - Mayo Clinic

    Hemoglobin ≥ 8 g/dL (obtained ≤ 14 days prior to randomization). Untransfused platelet count ≥ 75,000 cells/mm^3 (obtained ≤ 14 days prior to ...